RxDoctor Payments Data

James Rabalais, MD

Pain Medicine · Lafayette, LANPI 1740691831

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,573 of the $10,019 with a category attached, or 75.6%. 20 manufacturers reported payments, led by Nevro Corp. at 31.6% of the total.

$10,019in general payments, 2019–2025

Across 199 payments — averaging $50.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$3K
  • Boston Scientific$1K
  • Saluda Medical Americas, Inc.$1K
  • Stryker$1K
  • Medtronic$1K
  • Abbott$796
  • plus $874 from 14 others

What the payments were for

  • Travel & lodging$2,44624%
  • Food & beverage$7,57376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,019 in reported general payments places this provider in the 80th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$199,131
Medicare patients
366
Services billed
2,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate120$105,925
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,721$43,372
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,350$39,934
OxycontinOxycodone Hcl22$21,774
MovantikNaloxegol Oxalate51$21,568
Gabapentin1,130$14,885
Fentanyl104$12,945
Pregabalin882$12,310
Diflorasone Diacetate17$11,954
Hysingla ErHydrocodone Bitartrate19$9,487
Morphine Sulfate ErMorphine Sulfate377$8,084
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc55$7,797
Lidocaine75$7,205
Lidocaine-PrilocaineLidocaine/Prilocaine99$5,393
Methadone Hcl383$5,343

Paid to pharmacies, not to this prescriber.

Other pain medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →